Melanoma Abstracts ASCO 2016:

Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs. docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE) (First Author: Sara A. Hurvitz)

Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: Five-year outcomes of NSABP protocol B-41 (First Author: Andre Robidoux)

ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: A MICHELANGO study (First Author: Luca Gianni)

Preliminary outcome of a primary care-based skin cancer screening program (First Author: Laura Ferris)

Impact of aspirin use on the incidence of head and neck cancers: A systematic review and meta-analysis (First Author: Prakash C. Neupane)

Risk of male breast cancer in users of testosterone 5a reductase inhibitors (First Author: Hakan Lars Olson)

The opportunity cost (OC) of low adherence with screening (Scr) recommendations for colorectal cancer (CRC) (First Author: Afsaneh Barzi)

Screening with low-dose computed tomography (LDCT) of asbestos-exposed subjects and lung cancer (LC) mortality (First Author: Gianpiero Fasola)

Application of the 2015 American Cancer Society screening mammography guidelines: Risk assessment for women aged 40-44 (First Author: Jennifer Kay Plichta)

Use and adherence to breast cancer risk-reduction agents: A population-based study (First Author: Mariana Chavez-Mac Gregor)

Rethinking the Hispanic advantage in cancer outcomes: Influence of birthplace (First Author: Paulo Pinheiro)